Neuromuscular Blocker
Pregnancy: C
Rocuronium
Brand names: Esmeron
Adult dose
Dose: RSI: 1.2mg/kg IV. Standard intubation: 0.6mg/kg IV
Route: IV
Frequency: Single dose
Max: 120mg
RSI: 1.2mg/kg provides intubating conditions within 60–90 sec. Standard dose 0.6mg/kg: onset 3 min, duration 30–40 min. Reversal: sugammadex 16mg/kg (RSI dose) or 4mg/kg (standard dose).
Paediatric dose
Dose: 0.6 mg/kg
Route: IV
Frequency: Single intubating dose
Max: 50mg
Concentration: 10 mg/ml
Paediatric weight-based calculator
Clinical pearls
- Preferred over suxamethonium when hyperkalaemia risk, malignant hyperthermia history, or known neuromuscular disease.
- Sugammadex (16mg/kg) reverses RSI dose rocuronium within 3 min — critical lifeline in CICO (cannot intubate, cannot oxygenate) scenario.
- Keep sugammadex immediately accessible at every RSI. 200mg vials — adult RSI typically requires 4 vials (80kg patient).
- At 1.2mg/kg: intubating conditions within 60 sec, duration 60–90 min. Plan for sustained ventilation.
Contraindications
- Hypersensitivity to rocuronium or bromide
- Myasthenia gravis (extreme sensitivity — use very low doses only if essential)
Side effects
- Prolonged neuromuscular blockade
- Anaphylaxis (rare — more frequent than suxamethonium)
- Histamine release (rare — less than atracurium)
- Bronchospasm
Interactions
- Volatile anaesthetics: enhance and prolong block
- Aminoglycosides: enhance and prolong block
- Sugammadex: reversal — 16mg/kg for immediate RSI reversal
Monitoring
- Neuromuscular monitoring (TOF)
- clinical signs of recovery
Reference: BNFc; NICE BNF 84; DAS RSI Guidelines 2015; Difficult Airway Society. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Train-of-Four (TOF) Neuromuscular Monitoring · Neuromuscular Blockade
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- New Ballard Score — Gestational Age Assessment · Gestational Age
- MGFA Clinical Classification for Myasthenia Gravis · Neuromuscular
- Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale · Neuromuscular
Pathways
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
- Syncope Assessment · ESC 2018 Syncope Guidelines; NICE NG109
- Acute Chest Pain · NICE CG95; ESC 2023 ACS Guidelines